Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1997-06-02
2000-08-01
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241431, 4241521, 4241551, 4241721, 4241741, 4241381, 5303873, 5303882, 53038822, 53038825, 5303887, A61K 39395, C12P 2108, C12K 1600
Patent
active
060963115
ABSTRACT:
Monoclonal antibodies which react specifically to Fc receptor of human effector cells are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
REFERENCES:
Waldmann (Science, 252:1657-1662), 1991.
Hird (in Genes and Cancer, Carney and Sikora, eds, John Wiley & Sons, Chichester, pp. 183-189), 1990.
Harris et al (TIBTECH, 11;42-44), 1993.
Kimmel et al (J. Neurosurg., 66:161-171), 1987.
Kahan (Cur. Opin. Immunol., 4:553-560), 1992.
Bach (TIPS, 14:213-216), 1993.
Fahey et al (Clin. Exp. Immunol., 88:1-5), 1992.
Schlom (in Broder, Molecular Foundations of Biology, Williams & Wilkins, Baltimore pp. 95-134), 1991.
Burmester et al (Baillieres Clinical Rheumatology, 6:415-434), 1992.
Anderson Clark L.
Fanger Michael W.
Guyre Paul M.
DeConti, Jr. Giulio A.
Hutzell Paula K.
Medarex
Remillard Jane E.
Ungar Susan
LandOfFree
Methods for use of monoclonal antibodies specific for the high a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for use of monoclonal antibodies specific for the high a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for use of monoclonal antibodies specific for the high a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-661015